Company Description
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS).
Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death.
The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017.
Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
| Country | United States |
| IPO Date | Jul 19, 1990 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 189 |
| CEO | Dr. Mitchell S. Steiner F.A.C.S., M.D. |
Contact Details
Address: 2916 N. Miami Avenue, Suite 1000 Miami, Florida 33127 United States | |
| Phone | (312) 595-9123 |
| Website | verupharma.com |
Stock Details
| Ticker Symbol | VERU |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0000863894 |
| CUSIP Number | 92536C103 |
| ISIN Number | US92536C1036 |
| Employer ID | 39-1144397 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mitchell S. Steiner F.A.C.S., M.D. | Chairman, President and Chief Executive Officer |
| Dr. Harry Fisch F.A.C.S., M.D. | Vice Chairman and Chief Corporate Officer |
| Michele Greco | Chief Financial Officer and Chief Administrative Officer |
| Dr. K. Gary Barnette Ph.D. | Chief Scientific Officer |
| Samuel Fisch | Executive Director of Investor Relations and Corporate Communications |
| Michael J. Purvis | Executive Vice President, General Counsel and Corporate Strategy and Secretary |
| Kevin J. Gilbert CPA, J.D. | Executive Vice President of Corporate Development |
| Martin Tayler | Executive Vice President of FC2 Global Operations |
| Philip R. Greenberg J.D. | Executive Vice President and Deputy General Counsel |
| Dr. Domingo Rodriguez M.D. | Executive Vice President of Global Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | 8-K | Current Report |
| Apr 24, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 1, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 1, 2024 | 10-Q | Quarterly Report |
| Apr 1, 2024 | 10-K/A | [Amend] Annual report |
| Mar 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Feb 15, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |